A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model

Journal of Immunology

Volumn 177, Issue 1, 2006, Pages 155-161

  McWilliams, Jennifer A ^c   McGurran, Sean M ^a   Dow, Steven W ^b   Slansky, Jill E ^c   Kedl, Ross M ^c,d  

^a 3M COMPANY   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; TYROSINASE RELATED PROTEIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS REACTION; FEMALE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MODEL;

EID: 33745322115     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.1.155     Document Type: Article

References (51)

1. Diehl, L., A. T. den Boer, S. P. Schoenberger, E. I. van der Voort, T. N. Schumacher, C. J. Melief, R. Offringa, and R. E. Toes. 1999. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5: 774-779.
2. Marzo, A. L., R. A. Lake, B. W. Robinson, and B. Scott. 1999. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res. 59: 1071-1079.
3. Morgan, D. J., H. T. Kreuwel, S. Fleck, H. I. Levitsky, D. M. Pardoll, and L. A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160: 643-651.
4. Prevost-Blondel, A., C. Zimmermann, C. Stemmer, P. Kulmburg, F. M. Rosenthal, and H. Pircher. 1998. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J. Immunol 161: 2187-2194.
5. + T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J. Immunol. 162: 2858-2866.
6. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5: 780-787.
7. Bachmann, M. F., T. M. Kundig, G. Freer, Y. Li, C. Y. Kang, D. H. Bishop, H. Hengartner, and R. M. Zinkernagel. 1994. Induction of protective cytotoxic T cells with viral proteins. Eur. J. Immunol. 24: 2228-2236.
8. + T cells in the absence of tumor-antigen vaccination. Proc. Natl. Acad. Sci. USA 98: 10811-710816.
9. Wang, R. F., E. Appella, Y. Kawakami, X. Kang, and S. A. Rosenberg. 1996. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184: 2207-2216.
10. Rosenberg, S. A. 2000. Identification of cancer antigens: impact on development of cancer immunotherapies. Cancer J. 6(Suppl. 3): S200-S207.
11. Restifo, N. P., and S. A. Rosenberg. 1999. Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr. Opin. Oncol. 11: 50-57.
12. Marincola, F. M., E. M. Jaffee, D. J. Hicklin, and S. Ferrone. 2000. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74: 181-273.
13. Gattoni-Celli, S., and D. J. Cole. 1996. Melanoma-associated tumor antigens and their clinical relevance to immunotherapy. Semin. Oncol. 23: 754-758.
14. Mazzocchi, A., W. J. Storkus, C. Traversari, P. Tarsini, M. J. Maeurer, L. Rivoltini, C. Vegetti, F. Belli, A. Anichini, G. Parmiani, and C. Castelli. 1996. Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes. J. Immunol. 157: 3030-3038.
15. Bloom, M. B., D. Perry-Lalley, P. F. Robbins, Y. Li, M. el-Gamil, S. A. Rosenberg, and J. C. Yang. 1997. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185: 453-459.
16. + T lymphocytes. Proc. Natl. Acad. Sci. USA 96: 2982-2987.
17. Overwijk, W. W., A. Tsung, K. R. Irvine, M. R. Parkhurst, T. J. Goletz, K. Tsung, M. W. Carroll, C. Liu, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188: 277-286.
18. van Elsas, A., R. P. Sutmuller, A. A. Hurwitz, J. Ziskin, J. Villasenor, J. P. Medema, W. W. Overwijk, N. P. Restifo, C. J. Melief, R. Offringa, and J. P. Allison. 2001. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194: 481-489.
19. Xiang, R., H. N. Lode, T. H. Chao, J. M. Ruehlmann, C. S. Dolman, F. Rodriguez, J. L. Whitton, W. W. Overwijk, N. P. Restifo, and R. A. Reisfeld. 2000. An autologous oral DNA vaccine protects against murine melanoma. Proc. Natl. Acad. Sci. USA 97: 5492-5497.
20. Colella, T. A., T. N. Bullock, L. B. Russell, D. W. Mullins, W. W. Overwijk, G. J. Luckey, R. A. Pierce, N. P. Restifo, and V. H. Engelhard. 2000. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J. Exp. Med. 191: 1221-1232.
21. Bronte, V., E. Apolloni, R. Ronca, P. Zamboni, W. W. Overwijk, D. R. Surman, N. P. Restifo, and P. Zanovello. 2000. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res. 60: 253-258.
22. Overwijk, W. W., and N. P. Restifo. 2001. Creating therapeutic cancer vaccines: notes from the battlefield. Trends Immunol. 22: 5-7.
23. + T cells. Eur. J. Immunol. 31: 1910-1916.
24. Chaux, P., R. Luiten, N. Demotte, V. Vantomme, V. Stroobant, C. Traversari, V. Russo, E. Schultz, G. R. Cornelis, T. Boon, and P. van der Bruggen. 1999. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J. Immunol. 163: 2928-2936.
25. + T lymphocytes. J. Exp. Med. 189: 767-778.
26. + cytolytic T lymphocytes. Cancer Res. 60: 6272-6275.
27. Lee, P. P., C. Yee, P. A. Savage, L. Fong, D. Brockstedt, J. S. Weber, D. Johnson, S. Swetter, J. Thompson, P. D. Greenberg, et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5: 677-685.
28. Yee, C., P. A. Savage, P. P. Lee, M. M. Davis, and P. D. Greenberg. 1999. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162: 2227-2234.
29. de Visser, K. E., T. A. Cordaro, H. W. Kessels, F. H. Tirion, T. N. Schumacher, and A. M. Kruisbeek. 2001. Low-avidity self-specific T cells display a pronounced expansion defect that can be overcome by altered peptide ligands. J. Immunol. 167: 3818-3828.
30. de Visser, K. E., T. A. Cordaro, D. Kioussis, J. B. Haanen, T. N. Schumacher, and A. M. Kruisbeek. 2000. Tracing and characterization of the low-avidity self-specific T cell repertoire. Eur. J. Immunol. 30: 1458-1468.
31. 209-217-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J. Immunol. 162: 1749-1755.
32. Dionne, S. O., M. H. Smith, F. M. Marincola, and D. F. Lake. 2003. Functional characterization of CTL against gp100 altered peptide ligands. Cancer Immunol. Immunother. 52: 199-206.
33. Denkberg, G., E. Klechevsky, and Y. Reiter. 2002. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies. J. Immunol. 169: 4399-4407.
34. Thompson, L. W., C. F. Garbee, S. Hibbitts, L. H, Brinckerhoff, R. A. Pierce, K. A. Chianese-Bullock, D. H. Deacon, V. H. Engelhard, and C. L. Slingluff, Jr. 2004. Competition among peptides in melanoma vaccines for binding to MHC molecules. J. Immunother. 27: 425-431.
35. Slansky, J. E., F. M. Rattis, L. F. Boyd, T. Fahmy, E. M. Jaffee, J. P. Schneck, D. H. Margulies, and D. M. Pardoll. 2000. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13: 529-538.
36. - dendritic cells. J. Immunol. 171: 1156-1163.
37. + T cell expansion with variable dependence on type I IFN. J. Exp. Med. 199: 775-784.
38. Kedl, R. M., W. A. Rees, D. A. Hildeman, B. Schaefer, T. Mitchell, J. Kappler, and P. Marrack. 2000. T cells compete for access to antigen-bearing antigen-presenting cells. J. Exp. Med. 192: 1105-1113.
39. Ljunggren, H. G., N. J. Stam, C. Ohlen, J. J. Neefjes, P. Hoglund, M. T. Heemels, J. Bastin, T. N. Schumacher, A. Townsend, K. Karre, et al. 1990. Empty MHC class I molecules come out in the cold. Nature 346: 476-480.
40. del Marmol, V., and F. Beermann. 1996. Tyrosinase and related proteins in mammalian pigmentation. FEBS Lett. 381: 165-168.
41. + T cell responses in vivo and in vitro. Proc. Natl. Acad. Sci. USA 96: 9781-9786.
42. Crawford, F., E. Huseby, J. White, P. Marrack, and J. W. Kappler. 2004. Mimotopes for alloreactive and conventional T cells in a peptide-MHC display library. PLoS Biol. 2: E90.
43. Kedl, R. M., B. C. Schaefer, J. W. Kappler, and P. Marrack. 2002. T cells down-modulate peptide-MHC complexes on APCs in vivo. Nat. Immunol. 3: 27-32.
44. Chen, W., J. McCluskey, S. Rodda, and F. Carbone. 1993. Changes at peptide residues buried in the major histocompatibility complex (MHC) class I binding cleft influence T cell recognition: a possible role for indirect conformational alterations in the MHC class I or bound peptide in determining T cell recognition. J. Exp. Med. 177: 869-873.
45. McEarchern, J. A., D. G. Besselsen, and E. T. Akporiaye. 1999. Interferon γ and antisense transforming growth factor β transgenes synergize to enhance the immunogenicity of a murine mammary carcinoma. Cancer Immunol. Immunother. 48: 63-70.
46. He, X., P. Luo, T. C. Tsang, T. Zhang, and D. T. Harris. 2005. Immuno-gene therapy of melanoma by tumor antigen epitope modified IFN-γ. Cancer Immunol. Immunother. 54: 741-749.
47. Seliger, B., U. Wollscheid, F. Momburg, T. Blankenstein, and C. Huber. 2001. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res. 61: 1095-1099.
48. Kedl, R. M., J. W. Kappler, and P. Marrack. 2003. Epitope dominance, competition and T cell affinity maturation. Curr. Opin. Immunol. 15: 120-127.
49. Yewdell, J. W., and J. R. Bennink. 1999. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17: 51-88.
50. Restifo, N. P. 2001. Hierarchy, tolerance, and dominance in the antitumor T-cell response. J. Immunother. 24: 193-194.
51. Parkhurst, M. R., E. B. Fitzgerald, S. Southwood, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1998. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 58: 4895-4901.